Logo image of BTI.CA

BIOASIS TECHNOLOGIES INC (BTI.CA) Stock Fundamental Analysis

TSX-V:BTI - TSX Venture Exchange - CA09064N1033 - Common Stock - Currency: CAD

0.005  0 (0%)

Fundamental Rating

0

Overall BTI gets a fundamental rating of 0 out of 10. We evaluated BTI against 21 industry peers in the Biotechnology industry. Both the profitability and financial health of BTI have multiple concerns. BTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTI has reported negative net income.
BTI had a negative operating cash flow in the past year.
BTI had negative earnings in 4 of the past 5 years.
BTI had negative operating cash flow in 4 of the past 5 years.
BTI.CA Yearly Net Income VS EBIT VS OCF VS FCFBTI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M

1.2 Ratios

BTI has a Return On Assets of -163.11%. This is comparable to the rest of the industry: BTI outperforms 41.67% of its industry peers.
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROIC N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTI.CA Yearly ROA, ROE, ROICBTI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

BTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTI.CA Yearly Profit, Operating, Gross MarginsBTI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

BTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BTI has been increased compared to 1 year ago.
BTI has a worse debt/assets ratio than last year.
BTI.CA Yearly Shares OutstandingBTI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
BTI.CA Yearly Total Debt VS Total AssetsBTI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

2.2 Solvency

Based on the Altman-Z score of -41.85, we must say that BTI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -41.85, BTI is doing worse than 70.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -41.85
ROIC/WACCN/A
WACC6.78%
BTI.CA Yearly LT Debt VS Equity VS FCFBTI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 1M -1M 2M -2M -3M

2.3 Liquidity

A Current Ratio of 0.11 indicates that BTI may have some problems paying its short term obligations.
With a Current ratio value of 0.11, BTI is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
A Quick Ratio of 0.11 indicates that BTI may have some problems paying its short term obligations.
The Quick ratio of BTI (0.11) is worse than 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
BTI.CA Yearly Current Assets VS Current LiabilitesBTI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.43% over the past year.
Looking at the last year, BTI shows a very strong growth in Revenue. The Revenue has grown by 613.97%.
The Revenue for BTI have been decreasing by -40.66% on average. This is quite bad
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%

3.2 Future

The Earnings Per Share is expected to decrease by -5.27% on average over the next years.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BTI.CA Yearly Revenue VS EstimatesBTI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
BTI.CA Yearly EPS VS EstimatesBTI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2020 2021 2022 2023 2024 2025 0 0.02 -0.02 -0.04 -0.06 -0.08

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTI.CA Price Earnings VS Forward Price EarningsBTI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTI.CA Per share dataBTI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

BTI's earnings are expected to decrease with -5.27% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOASIS TECHNOLOGIES INC

TSX-V:BTI (3/18/2024, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)01-26 2022-01-26
Inst Owners0.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap397.07K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -41.85
F-Score3
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-719.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-719.99%
OCF growth 3YN/A
OCF growth 5YN/A